


DRUG-BUG CROSSTALK IMPACTS COMPOSITIONAL AND FUNCTIONAL FEATURES OF IN VITRO GUT MICROBIAL ECOSYSTEM

Emma Hernandez-Sanabria¹, Evelien Heiremans¹, Fabian Mermans¹, Ruben Props¹, Marta Calatayud Arroyo¹, Laurent Leclercq², Jan Snoeys², and Tom Van de Wiele¹

¹ Center for Microbial Ecology and Technology (CMET), Ghent University, Coupure Links 653, 9000 Ghent, Belgium. ² Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse, Antwerp, 2340, Belgium.

Emma.HernandezSanabria@UGent.be

Microbiome as the next frontier for gut-targeted drugs



Using *in vitro* models for assessing drug-bug crosstalk

Screening for responsive/not responsive

Batch system

- 8 donors
- 16 h (proximal colon conditions)
- Clinical CX dose + carrier (PEG)




Long term supplementation M-SHIME system

• 2 donors

(PEG)

- 2wk stabilization +2wk
- treatment + 1wk washout
- Clinical CX dose + carrier







Approaches


 Microbiome functionality (GC) Community composition (NGS) Host interactions (cell models)

Interactions between microbial- and host-derived metabolism



Bacterially-exposed CX decreased inflammation





	End of stabilisation	One week of CX	End of treatment	End of washout	
100-					
80-	Meaamonas		Bifidobacterium		
	disappeared from	ι	appears		
60	mucus in D6	0			

	End of stabilisation	One week of CX	End of treatment	End of washout	After mucin removal
100-					
80-		• •	•		
60-					

We thank the support from Janssen Pharmaceutica, Racha El Hage and the staff from CMET. E.H-S is a postdoctoral fellow supported by Flanders Innovation and Entrepreneurship (Agentschap Innoveren & Ondernemen)